Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.

Abstract excerpt

Insulin resistance is known to unite several metabolic abnormalities. The associated dyslipidaemia appears to play a central role in this atherogenic syndrome. Thiazolidinediones, which are recently introduced insulin sensitizing agents, have been shown to be effective not only in reducing elevated glucose levels, but also in improving the other metabolic abnormalities that are associated with insulin resistance....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chromans
• Share to Clinical Trials as Topic
• Share to Glucose